CGEM - Cullinan Management, Inc. Stock Price, Fair Value and News

$13.29+0.12 (+0.91%)

Delayed as of 03 Dec 2024, 11:58 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CGEM Price Action

Last 7 days

5.0%

Last 30 days

-16.5%

Last 90 days

-28.8%

Trailing 12 Months

52.1%

CGEM RSI Chart

CGEM Valuation

Market Cap

766.9M

Price/Earnings (Trailing)

-6.84

Price/Sales (Trailing)

8.43

EV/EBITDA

-4.76

Price/Free Cashflow

-6.05

CGEM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CGEM Fundamentals

CGEM Revenue

Revenue (TTM)

107.4M

CGEM Earnings

Earnings (TTM)

-132.5M

Earnings Growth (Yr)

-3.51%

Earnings Growth (Qtr)

3.49%

CGEM Profitability

EBT Margin

-157.52%

Return on Equity

-21.1%

Return on Assets

-20.28%

Free Cashflow Yield

-16.54%

CGEM Investor Care

Shares Dilution (1Y)

36.11%

Diluted EPS (TTM)

-2.84

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2024	0	0	0
2023	0	0	0
2022	173.6M	140.5M	107.4M
2021	0	0	18.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cullinan Management, Inc.

Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Nadim Ahmed
WEBSITE	cullinanoncology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	62

Cullinan Management, Inc. Frequently Asked Questions

What is the ticker symbol for Cullinan Management, Inc.? What does CGEM stand for in stocks?

CGEM is the stock ticker symbol of Cullinan Management, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cullinan Management, Inc. (CGEM)?

As of Mon Dec 02 2024, market cap of Cullinan Management, Inc. is 766.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGEM stock?

You can check CGEM's fair value in chart for subscribers.

Is Cullinan Management, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGEM is over valued or under valued. Whether Cullinan Management, Inc. is cheap or expensive depends on the assumptions which impact Cullinan Management, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGEM.

What is Cullinan Management, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, CGEM's PE ratio (Price to Earnings) is -6.84 and Price to Sales (PS) ratio is 8.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGEM PE ratio will change depending on the future growth rate expectations of investors.